What is the role of PARP inhibitors in treating MDS

PARP Inhibitors in MDS Treatment

I appreciate this question, as it touches on an important area of MDS research. However, I need to be direct with you: based on the current NCCN Guidelines for Myelodysplastic Syndromes (Version 1.2026), PARP inhibitors are not listed as a standard treatment option for MDS.

What the Guidelines Show

According to the NCCN MDS Guidelines, the primary treatment approaches for MDS include:

For lower-risk disease:

• Supportive care (transfusions, growth factors)
• Lenalidomide (for del(5q) mutations)
• Erythropoiesis-stimulating agents (ESAs) like epoetin alfa
• Imetelstat and luspatercept (newer options for anemia)
• Immunosuppressive therapy for select patients

For higher-risk disease:

• Hypomethylating agents (azacitidine, decitabine)
• IDH inhibitors (ivosidenib for IDH1 mutations, enasidenib for IDH2 mutations)
• Allogeneic stem cell transplantation
• Clinical trials

Why Not PARP Inhibitors?

PARP inhibitors work by blocking DNA repair mechanisms and have shown benefit in cancers with specific genetic vulnerabilities (like BRCA mutations in breast cancer). While MDS involves genetic mutations, the current evidence doesn't support PARP inhibitors as a standard approach for this disease.

Important Questions to Ask Your Doctor

1. Are there any clinical trials involving PARP inhibitors for my specific MDS subtype? (Research is ongoing in various settings)
2. What mutations does my MDS have, and which treatments are recommended for those specific mutations?
3. Am I a candidate for any of the newer agents like imetelstat or luspatercept?
4. Should I be evaluated for a clinical trial?

The Research Frontier

While PARP inhibitors aren't standard MDS treatment now, cancer research is always evolving. If you're interested in emerging therapies, ask your oncologist about:

• Active clinical trials at your institution
• Precision medicine approaches based on your specific mutations
• Referral to an MDS specialist center

According to the NCCN Guidelines, treatment decisions should be based on your specific risk category (using the IPSS-R scoring system), your blast percentage, cytogenetic findings, and molecular mutations—all of which your doctor uses to personalize your care plan.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.